

This is a repository copy of Main salivary steroid collection in children under conditions replicating home sampling.

White Rose Research Online URL for this paper: <u>https://eprints.whiterose.ac.uk/189970/</u>

Version: Accepted Version

Article:

Tonge, J.J., Keevil, B.G., Craig, J.N. et al. (3 more authors) (2022) Main salivary steroid collection in children under conditions replicating home sampling. Journal of Clinical Endocrinology and Metabolism, 107 (11). dgac419. pp. 3128-3136. ISSN 0021-972X

https://doi.org/10.1210/clinem/dgac419

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



| 1 | Main Title: Salivary steroid collection in children under conditions replicating |
|----|--|
| 2 | home sampling |
| 3 | Short title: Salivary steroid collection in young children |
| 4 | Key Words: Adrenal insufficiency, Salivary, Cortisol, Cortisone, Stability, Collection device |
| 5 | |
| 6 | Joseph J. Tonge BSc ¹ , Brian G. Keevil PhD ² , Jessica N. Craig MBChB ¹ , Martin J. Whitaker |
| 7 | PhD ³ , Richard J. Ross MD ³ , Charlotte J. Elder PhD ^{3,4*} |
| 8 | ¹ Academic Unit of Medical Education, Medical School, University of Sheffield, Sheffield, UK |
| 9 | ² Department of Clinical Biochemistry, University Hospital of South Manchester NHS Trust, |
| 10 | Manchester, UK |
| 11 | ³ Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK |
| 12 | ⁴ Department of Endocrinology, Sheffield Children's NHS Foundation Trust, Sheffield, UK |
| 13 | * Corresponding author: <u>c.j.elder@sheffield.ac.uk</u> , +44 114 305 3282. Room 10, The Damer |
| 14 | Street Building, Sheffield Children's Hospital, Sheffield, UK. ORCID ID: 0000-0003-2390-5593. |
| 15 | |
| 16 | Funding: CJE and BK were supported by funding from UKRI Biomedical Sciences Innovation |
| 17 | Scholar secondments references MR/W002795/1 and 75781 respectively. We are grateful to |
| 18 | the Society for Endocrinology who part funded this with a student research grant for JJT. |
| 19 | For the purpose of open access, the author has applied a Creative Commons Attribution (CC |
| 20 | BY) licence to any Author Accepted Manuscript version arising. |
| 21 | |

- **Disclosure summary:** There is no conflict of interest that could be perceived as prejudicing
- 23 the impartiality of the research reported. JJT, BGK, JNC, MJW, RJR and CJE have nothing to
- 24 declare
- **ClinicalTrails.gov Registration Number**: NCT05350982

28 Abstract:

29

30 **Objective:** Measurement of salivary glucocorticoids is an accepted method for testing adrenal 31 function but there is little data on stability during home collection. Current salivary collection 32 techniques require active participation or present a choking hazard and are unsuitable for 33 young children. We sought to: compare different salivary collection methods; assess stability 34 of salivary glucocorticoids under conditions replicating home collection; assess patient 35 tolerability and caregiver acceptability of a salivary collection device for young children, a 36 swab encased in an infant pacifier (SaliPac[™]).

Methods: Six healthy adults collected salivary samples using a Salivette[®] Cortisol, passive drool and SalivaBio at night, waking and 3pm for five days. Time to collect 1ml saliva using the SalivaBio and SaliPac and caregiver acceptability were assessed in 30 children <6 years. Saliva was stored at 4°C, room temperature and 50°C for 24, 48, 72 hours and a week to replicate potential postage conditions. Salivary cortisol and cortisone concentrations were measured by mass spectrometry.

43 **Results:** There was no difference in salivary glucocorticoid concentrations using the three 44 collection methods. Salivary cortisol and cortisone were stable for 72 hours at room 45 temperature and 4°C, and repeated freeze-thaw cycles did not cause significant degradation. 46 In children <6 years the SalivaBio and SaliPac were well tolerated and collected sufficient 47 saliva for salivary steroid analysis in <4 minutes.</p>

48 Conclusions: Salivette, passive drool and SalivaBio collect samples with comparable salivary
 49 cortisol and cortisone concentrations, which are stable under conditions replicating home
 50 collection. SaliPac is an acceptable device for salivary sampling in young children.

51

52 Introduction:

53 The measurement of glucocorticoids in salivary samples is becoming an accepted method for 54 diagnosing adrenal insufficiency and Cushing's syndrome (1, 2, 3). In the salivary gland, 55 plasma free cortisol is rapidly converted to inactive cortisone by 11ß-hydroxysteroid 56 dehydrogenase-type-2 and there is a close correlation between biologically active free serum 57 cortisol and salivary cortisol and cortisone (4, 5). Salivary sampling offers a non-invasive 58 collection technique, enabling home sampling with postage to the laboratory, facilitating 59 tailored capture of steroid circadian rhythm and an improved patient experience (6). Salivary 60 measurement allows assessment of adrenal status in patients with altered cortisol binding 61 proteins, where total serum cortisol is difficult to interpret, such as pregnancy, liver disease 62 and oral contraceptive pill users (1).

63

64 There are numerous salivary collection techniques using both absorptive methods (cotton 65 buds, filter paper, eye sponges, cotton dental rolls, generic swabs and specialised swabs) and 66 aspiration (pipette and syringe connected to tubing). The Salivette® (Sarstedt, Germany) and 67 passive drool are widely used (7, 8), with Salivette[®] Cortisol (Sarstedt, Germany) developed 68 in response to studies demonstrating that cotton significantly compromises salivary cortisol 69 samples (6, 9, 10). The Salivette presents a choking hazard and both Salivette and passive 70 drool require active patient participation, making them unsuitable for young children. 71 Aspiration is reported to result in high rates of insufficient salivary volumes for analysis and 72 risks damaging delicate mucous membranes leading to blood contaminated samples (6, 11). 73 Our experience is that children younger than six years are unlikely to comply with passive 74 drooling. The SalivaBio Infants and Children's swabs (Salimetrics, USA) are synthetic and

intended for children aged under six months and six months to six years respectively;
however, there is a paucity of data on their efficacy, reliability, and tolerability (6, 12).

77

78 Accurate diagnostic screening for hypo- and hyper-cortisolism requires sampling outside of 79 traditional working hours, either first thing in the morning for adrenal insufficiency or last 80 thing at night for Cushing's. Early morning serum cortisol as a screening test for adrenal 81 insufficiency is flawed as there is a requirement for the patient to attend a healthcare setting 82 for testing, by which time the natural cortisol peak experienced soon after waking is waning. 83 This results in poor predictive value, leading to recommendations for time- and resourceconsuming invasive diagnostic tests (13). It is therefore impractical to use venous sampling in 84 85 many settings and home collection of salivary glucocorticoids, with postage of samples to the 86 laboratory, addresses this issue. Previously published work has reported no significant change 87 in salivary cortisol concentration when stored at 4°C or 20°C for up to 84 days, but that salivary 88 steroids are more stable when stored refrigerated compared to room temperature (14, 15). 89 To our knowledge there are no publications reporting salivary cortisone sample stability. To 90 facilitate the global utility of salivary steroid measurement, with collection in rural and remote 91 settings, data are required on the stability of both salivary glucocorticoids stored under 92 different conditions and temperatures.

93

There is increasing recognition of the risk of adrenal insufficiency due to glucocorticoid suppression in neonates and children (16, 17, 18). Furthermore, with both steroid prescriptions and requests for adrenal function testing rising in the paediatric population (19, 20), there is a requirement for a simple, effective and patient friendly screening test for adrenal insufficiency suitable for infants and young children. Lack of a robust validated

99 salivary collection technique for this cohort has hampered salivary steroid research, 100 specifically, the construction of paediatric normative reference data. The ability to measure 101 salivary steroids in this young cohort would facilitate diagnosis of adrenal insufficiency, but a 102 safe and reliable method for collecting saliva is required.

103

104 To support the development of paediatric salivary steroid measurement, we have 105 investigated different collection methods and salivary glucocorticoid stability under 106 conditions simulating home collection.

107

108 Methods

109

110 Salivary steroid collection techniques studied: We studied three salivary collection 111 techniques: Salivette Cortisol (Figure 1a), passive drool (Figure 1b) and SalivaBio (Figure 1c). The Salivette[®] Cortisol swab (Sarstedt, Germany) is a biocompatible synthetic fibre roll 112 113 chewed for two minutes then placed in a transportation tube. In the laboratory, the Salivette 114 is centrifuged in the transportation tube at 1,500-3,000g for ten minutes at 4°C. The saliva is 115 frozen, preventing bacterial growth, until analysis (21). Passive drool uses a straw or collection 116 aid to guide saliva into a receptacle with volume markers (22). Saliva is viscous and contains 117 air bubbles, making it difficult to gauge the exact volume collected by passive drool (23). The 118 SalivaBio (Salimetrics, USA), is a 12cm synthetic non-cotton polymer swab. Approximately 119 2cm is placed in the mouth with the other end held by the patient or caregiver until the lower 120 third is saturated, taking on average 2.5 minutes (24). The SalivaBio is centrifuged after 121 collection in a 'swab basket' allowing drainage of saliva through the bottom of the tube.

122

123 Salivary collection technique comparison study: To compare the different techniques we 124 conducted a prospective study in six healthy adult volunteers. The exclusion criteria were: 125 pregnancy; known alcohol or drug misuse; current or recent (within six months) smoker or 126 vaper; symptoms of uncontrolled infection, past or present history of salivary gland or oral 127 mucosal pathology; protein losing disorders; liver disease; current or recent treatment with 128 any formulation of glucocorticoids or drugs known to affect cortisol binding globulin including 129 oestrogen, loperamide and opiates; recent liquorice ingestion; or history of hypothalmo-130 pituitary-adrenal axis pathology. We provided participants with Salivette Cortisol swabs, 131 SalivaBio swabs, passive drool kits (SaliCap (IBL international, Germany)) and written 132 instructions. Participants provided salivary samples using each of the techniques, in a 133 randomised pre-determined order, at three specified time points: awakening, 3pm and on 134 retiring for bed, on five days (45 samples per participant). We asked participants not to eat, 135 drink, brush or floss their teeth for 60 minutes prior to sampling. Samples collected at home 136 were immediately refrigerated, then centrifuged and the saliva frozen in the laboratory the 137 following day until thawing for batch analysis.

138

Development of a new salivary collection technique for young children – SaliPacTM: We modified the SalivaBio swab to create an alternative collection method for use in neonates, infants and young children, the SaliPacTM (Figure 2). Using sterile scissors, we cut 8cm of the swab and made a 1cm incision in the pacifier teat, securing the swab within the teat with 5mm protruding to facilitate salivary absorption. An indicator line was added at 6cm using a chromatography pen providing a visual prompt at ~1mL of saliva collected. In a pilot study we compared the salivary cortisol and cortisone levels after collection with the SaliPac and SalivaBio and found SalivaBio modification and introduction of the pacifier did not impactsalivary glucocorticoid recovery.

148

149 Salivary steroid stability and freeze-thaw studies: To mimic postage of salivary samples to a 150 central laboratory we examined the effects of time and temperature on salivary steroid 151 stability. We provided the same six healthy adult volunteers with SaliCaps to collect saliva by 152 passive drool at 9am or 4pm. Saliva was separated into 16 aliquots by pipetting a minimum 153 of 250ul onto a SalivaBio swab in a transportation tube. Four reference samples from each 154 participant were immediately frozen at -80°C (time zero) and other samples stored at either 155 4°C, room temperature or 50°C for 24 hours, 48 hours, 72 hours or one week and then frozen. 156 Additionally, we examined salivary glucocorticoids stability after one, two, three and four 157 freeze-thaw cycles. Each thaw was for one hour and each freeze cycle lasted one hour at -158 80°C.

159

Salivary cortisol and cortisone assay: We quantified salivary cortisol and cortisone in all the salivary samples by liquid chromatography-tandem mass spectrometry (LCMS) using a Waters Xevo TQ-MS mass spectrometer and a Waters Aquity LC system with electrospray source operated in positive-ionization mode. For both salivary glucocorticoids lower limits of quantitation were 0.83 nmol/L. Inter-assay coefficient of variability (CV) were 9.7% and 10.3% and intra-assay CV were 9.3% and 7.9% at <2.76-52.42 nmol/L of salivary cortisol and 2.76-96.57 nmol/L of cortisone, respectively (25, 26).

167

SalivaBio and SaliPac feasibility study: A prospective single site, feasibility study in young
 children to assess the utility and tolerability of the SalivaBio and SalivaBio + pacifier (SaliPac)

170 was performed. Our objectives were to determine whether the devices can collect 0.2ml of 171 saliva, the minimum salivary volume required for LCMS analysis, in an acceptable time frame; 172 and determine participant acceptability and ease of use for caregivers. We recruited 30 173 children under six years from the outpatient department or inpatient wards at Sheffield 174 Children's NHS Foundation Trust, UK; six from each age band: <6 months, 6-12 months, 1-2 175 years, 2-3 years and 3-5 years. Participants were excluded only if they had a mouth pathology 176 precluding painless salivary collection. Data were collected on previous or current pacifier 177 use, finger/thumb sucking, breastfeeding and whether the participant was being fed by 178 nasogastric tube. Participants sampled using the SalivaBio and SaliPac in a pre-determined 179 randomised order. The salivary samples were collected by the caregiver with a member of 180 the study team timing the collection and noting any difficulties. We recorded two timings: 181 first, the total time taken from the swab entering the child's mouth to the indicator line 182 moving (i.e., completion of the 1ml sampling) which we have called "real-world collection 183 time". This represents the length of time for a salivary collection when undertaken at home, inclusive of any additional time e.g., when the child spits out the swab or refuses to have it 184 185 back in their mouth. The second timing was the time taken for the indicator line to move, but 186 with the clock stopped each time the device was expelled from the mouth. We called this 187 "actual collection time" as it reflects solely the time taken for the swab to absorb 1mL of 188 saliva. The difference in real-world and actual collection times was used as a surrogate marker 189 of device tolerability. We randomly selected ten participants to simulate home conditions by 190 carrying out sampling using only our instruction leaflet, with no guidance from the study 191 team. Following collection, we reweighed the swabs (on a single set of calibrated three 192 decimal place scales), allowing volume of saliva to be calculated from the difference in mass 193 of the tube before and after collection. Caregivers were asked to complete a simple 21-

question questionnaire developed in-house [(supplementary material(27)] to assess the
 acceptability of the collection techniques.

196

Ethics: The studies were approved by the Yorkshire and Humber Sheffield Research Ethics
 committee and written informed consent obtained from all caregivers. ClinicalTrails.gov
 NCT05350982.

200

201 Statistical analysis: The data were analysed using IBM® SPSS® Statistics (version 27). 202 Differences in collection techniques were quantified by pairwise comparison, using a one 203 samples t-test on both pairs. Statistical significance was set at 5% (p<0.05). Mean, standard 204 deviation (SD) and range for binary outcomes and medians in cases of skewed distribution 205 were calculated. Percentage median differences were used to compare samples collected in 206 the stability study. A practical limit of >10% of baseline concentration was considered as 207 clinically significant degradation as this exceeds the inter-assay CV for the assays. Percentage 208 median difference was calculated for non-binary results requiring comparison to baseline 209 concentration. Paired samples t-test were used to compare effect of storage conditions on 210 baseline salivary steroid concentration.

211

212 **Results**

213

Salivary collection technique comparison study: The six healthy adult volunteers (2F) who
participated in the cross validation and stability studies had a mean age of 46 years (range 3263). A total of 270 salivary samples, 45 from each of the six participants, were collected. We
compared salivary cortisol and cortisone values from the three techniques (Table 1) and found

218 no significant difference. When comparing SalivaBio and Salivette there was a mean 219 difference of -0.226 nmol/L (95% CI -0.957 to 0.410) and -1.516 nmol/L (95% CI -4.242 to 220 1.210) in the measurement of salivary cortisol and cortisone, respectively. The comparison 221 between SalivaBio and passive drool produced a mean difference of -0.751 nmol/L (95% CI -222 2.928 to 1.425) and 0.871 nmol/L (95% CI -3.001 to 4.745) in salivary cortisol and cortisone, 223 respectively. The mean differences for salivary cortisol and cortisone when collected using 224 the Salivette and passive drool were 0.214 nmol/L (95% CI -1.087 to 1.729) and 1.029 nmol/L 225 (95% CI -2.280 to 4.338) respectively.

226

227 Salivary steroid stability and freeze-thaw studies: We collected 96 samples in total; 24 stored 228 for each of the following times: 24, 48, 72 hours and one week; and 32 at each of the following 229 conditions: room temperature (RT); refrigerated or 50°C. The mean salivary cortisol and 230 cortisone concentration of the reference samples frozen immediately after collection were 231 3.675 nmol/L (SD 1.914) and 21.70 nmol/L (SD 8.21) respectively. Overall time and 232 temperature increased degradation of salivary glucocorticoids (Figure 3). A significant 233 difference in mean salivary cortisol, indicating statistically significant degradation, was 234 observed in samples stored at both RT (p=0.041) and 50°C (p=0.044) for one week (Table 2). 235 Salivary cortisone showed significant degradation at all time points at 50°C (p=0.048 at 24 236 hours, p=0.002 at 48 hours, p=0.009 at 72 hours and p=0.012 at one week) and when stored 237 at RT for a week (p=0.012) (Table 3). There was a less than 10% median change in salivary 238 cortisol out to a week for samples kept at RT (% median change (95% CI) -2.02% (1.61-9.75)) 239 and refrigerated (-8.82% (-2.22 to -22.99)). This was similar for samples stored at 50°C until 240 72 hours (-6.54% (-0.10 to -20.62)), but by a week there was significant degradation (-20.99% 241 (-2.5 to -31.14)). Salivary cortisone degraded faster than salivary cortisol at 50°C with samples

having a greater than 10% median change by 48 hours (-11.74% (-7.54 to -16.62)) and showing marked degradation by one week (-25.62% (-19.80 to -42.39)). Salivary cortisone samples showed minimal degradation when refrigerated out to a week (-3.40 (-0.63 to -12.32) and at RT for 72 hours (-5.27 (-3.08 to -13.02)) but had degraded by just over 10% median change by one week (-10.83% (-8.02 to -14.23)). Repeated freeze-thaw cycles did not result in significant degradation with the maximum median change in cortisol -2.69% (-18.5 to -3.29) and in cortisone -1.69% (-12.21 to -3.45), both following four cycles (Figure 4).

249

250 SalivaBio and SaliPac feasibility study: All 30 children (13F) recruited to our paediatric 251 feasibility study successfully completed their visits. Participants had a mean age of 1.98 years 252 (SD 1.6 years, range 11 days to 5 years 10 months). Half of the participants had used a pacifier 253 (30% currently) for an average of 14 months. Two children were currently finger or thumb 254 suckers (none with a past history). Breastfed children made up 40% of the cohort (15% 255 currently) with a mean duration of 6.9 months (range 11 days to 19 months). One child had a 256 nasogastric tube in situ. Four caregivers did not wish their child to trial the SaliPac, all from 257 the group who had never used a pacifier, resulting in data from 30 samplings using the 258 SalivaBio and 26 with the SaliPac. The required minimum volume of 0.2ml of saliva was 259 collected in all 56 samplings. The full 1ml was collected in 47 (84%) samplings, >0.8ml in 52 260 (93%) with the smallest volume, 0.34 ml, collected from a sleeping child. Previous or current 261 pacifier use significantly shortened time to collect 1ml of saliva (p=0.021), but a history of 262 breastfeeding or finger/thumb sucking did not have an impact. The mean time to collect ~1ml 263 of saliva (time to indicator change) using the SalivaBio was 122 seconds (SD 37, range 42-210) 264 and 132 seconds (SD 31, range 73-229) using the SaliPac. There were no significant differences

in collection times between the two devices overall (p=0.319) or using the "real-world" versus
"actual" collection times (p=0.146) (Table 4).

267

268 Questionnaire analysis demonstrated that all caregivers thought the salivary collection time 269 was acceptable for both devices (mean score 10/10). Of the 26 who sampled using both, 21 270 stated they preferred the SaliPac, three the SalivaBio and two reported no preference. Three 271 commented that the SaliPac "looked safer". Caregivers reported a high level of acceptability 272 for both SalivaBio (mean score of 8.2/10 (range 7-10)) and SaliPac (9.8/10 (range 8-10)) and 273 collection to be easy using both devices (SalivaBio mean score 8.2/10 (range 6-10), SaliPac 9.2 274 (range 8-10)) (Table 5). All caregivers felt confident overseeing a salivary collection from their 275 child at home using our Patient Information Leaflet.

276

277 Discussion

278

279 Our studies have demonstrated no significant difference in salivary cortisol or cortisone when 280 collected using the commonly used techniques: Salivette, passive drool, and SalivaBio. We 281 found salivary glucocorticoids degrade over time at the highest temperature studied (50°C) 282 but demonstrate good stability of up to a week when kept at room temperature or 283 refrigerated. Salivary glucocorticoids were unaffected by repeated freeze-thaw cycles. The 284 SalivaBio swab, and our modified SaliPac, collected sufficient saliva for glucocorticoid analysis 285 in under four minutes in all participants, and in two minutes in the majority. Both were well 286 tolerated by the children and acceptable to caregivers, who felt confident that they could 287 successfully perform home salivary collection.

289 Stability of salivary cortisol collected by Salivette, and passive drool has been demonstrated 290 previously under a variety of storage conditions (laboratory and domestic freezer, 291 refrigerated and room temperature), with the optimum storage condition room temperature 292 (typically 20-23 °C) (14, 15). Salivary cortisol remains stable for at least 72 hours, with some 293 studies reporting minimal degradation out to a week and far beyond (14, 15, 28, 29). To our 294 knowledge there are no studies reporting stability of salivary cortisone, saliva collected using 295 a SalivaBio swab or salivary glucocorticoids analysed by gold standard LCMS methodology. 296 Cortisone is emerging as the preferred salivary biomarker in adrenal insufficiency, as it better 297 reflects plasma free cortisol, is the more abundant salivary glucocorticoid and demonstrates greater sensitivity at low serum cortisol levels (4, 5). Our work has demonstrated salivary 298 299 cortisone stability, especially when refrigerated, or for at least 72 hours at room temperature, 300 providing reassurance that patients being investigated for hypo- or hypercortisolism can 301 collect samples at home and post them back to the laboratory for analysis. Previous studies 302 have shown repeated freeze-thaw cycles do not accelerate degradation of salivary cortisol, 303 although good laboratory practice dictates these should be kept to a minimum (18,20). We 304 have demonstrated this for salivary cortisol and cortisone facilitating global utility of salivary 305 glucocorticoid use. Samples taken in rural, remote or resource poor settings can be posted to 306 the local healthcare provider, frozen, then posted on to a central laboratory, where they may 307 be refrozen before LCMS analysis.

308

309 Other groups have recognised the requirement for a simple, patient friendly and effective 310 salivary screening test for adrenal insufficiency suitable for infants and young children. A 311 recent study described a pacifier based salivary collection device but it was unable to collect 312 saliva successfully from children under five months of age (15). Sorbettes (eye sponges) were

313 used previously for paediatric salivary collection, however the cotton material was found to 314 bind salivary cortisol (30). Pipettes have been trialled but either required a salivary stimulant 315 or failed to collect successfully in neonates (31, 32). One study investigated a pipette for home 316 use but 16% of participants disliked the technique and no one collected the required 0.5mL 317 (33). Universal cotton swabs have been used in clinical studies with varying success. One study 318 tested them in 65 extreme premature infants, however the method required four swabs 319 placed sequentially in the mouth for 1-2 minutes and 15% collected insufficient volumes for 320 analysis (34). Cotton is now widely acknowledged to be an inappropriate material for salivary 321 glucocorticoid collection (6, 9, 10). The SalivaBio and our modification, the SaliPac, provide 322 easy, efficient and well tolerated methods to collect saliva samples from neonates, infants 323 and young children addressing the unmet needs of current collection techniques. They could 324 also have utility in adult cohorts where salivary collection may be challenging e.g., patients 325 with altered cognition such as those with dementia or learning difficulties; or reduced 326 conscious level such as those on intensive care.

327

328 Home salivary collection can reduce the need for hospital visits and facilitate collection of 329 multiple timed samples. For the widespread clinical adoption of salivary glucocorticoids in the 330 assessment of adrenal function, patients and their caregivers need to be able to comply with 331 home testing protocols and post the samples back to the hospital/laboratory. A recent study 332 of 19 healthy adults (mean age 42 years, 50% female) required to collect four salivary samples 333 per day over three consecutive days and at two time points, reported high levels of 334 adherence; with 95% adhering to the correct number of samples in the protocol and 84% to 335 the specified timings (three on or soon after awakening and one on retiring for bed) (35). 336 Other studies of home salivary collection in adults have shown similar results, with good

compliance and high rates of acceptability (36, 37) and studies in children have reported levels
of compliance above 90% in participants as young as 3.5 years (38, 39).

339

340 There are limitations of our studies. We analysed the impact of temperature and time on 341 salivary steroid stability, but did not combine storage conditions to mimic real life, with 342 different conditions experienced during the journey from patient to assay platform. A 343 previous study reported no impact of combining different storage conditions (28). We chose 344 the extreme temperature of 50°C to investigate the effect of heat on salivary glucocorticoid 345 stability and extrapolate to the utility of posting samples in tropical climes. Future studies 346 should include more commonly encountered temperatures e.g., 30°C, 35°C and 40°C under 347 controlled conditions with a larger sample size. We excluded volunteers with conditions 348 known to alter cortisol measurements (e.g., liver disease and pregnancy). High sensitivity and 349 specificity have been demonstrated between salivary and serum cortisol levels in pregnancy 350 and in those taking oestrogen containing contraceptive medication, and it is generally 351 acknowledged that salivary measurement facilitates adrenal assessment in patients with 352 altered cortisol binding proteins (1, 40, 41, 42). However we acknowledge that to assess the 353 future utility of salivary glucocorticoids in the screening and diagnosis of adrenal dysfunction 354 these groups would need to be studied. Although we attempted to recreate home conditions 355 for a cohort of participants and sought information about caregiver confidence performing 356 collections using the SalivaBio and SaliPac at home, caregiver numbers were small and all 357 visits were conducted in hospital. Whilst this detailed study on practicalities and techniques 358 provides the evidence that home measurement is possible, a further study involving a larger 359 number of caregivers, and conducted in the home setting, is required to test instructions to 360 caregivers and establish whether "real home" conditions yield similar results.

361 In conclusion, we have demonstrated no difference in salivary glucocorticoid concentrations collected using devices designed for very young children compared with the standard salivary 362 363 collection techniques of Salivette and passive drool. Both salivary cortisol and cortisone are 364 stable refrigerated and at room temperature to 72 hours and beyond, but salivary cortisone 365 rapidly degrades at extreme high temperatures. The SalivaBio alone and contained in our 366 novel modification, the SaliPac[™], collect sufficient salivary volumes for steroid analysis in 367 under four minutes, are easy to use and acceptable to children and caregivers. Our studies 368 provide data to support the use of these salivary collection techniques in patients under six 369 years of age, both for clinical indications and in research settings, enabling the construction 370 of normative reference ranges in young children and the study of paediatric adrenal function 371 in disease states.

372

Author Contributions: JJT and CJE designed the SaliPac device. JJT, BGK and CJE conducted
the studies. BGK performed the salivary glucocorticoid analysis. JJT analysed the data. CJE and
JJT wrote the paper and all authors designed the studies, contributed to reviewing protocols,
results, analysis and editing the manuscript.

377

378 Data availability: Some or all datasets generated during and/or analysed during the current
379 study are not publicly available but are available from the corresponding author on
380 reasonable request.

382 **References**

- 383 1. Raff H. Utility of salivary cortisol measurements in Cushing's syndrome and adrenal
- 384 insufficiency. The Journal of clinical endocrinology and metabolism 2009 94 3647–

385 3655. (doi:10.1210/JC.2009-1166)

- 386 2. Blair J, Adaway J, Keevil B, & Ross R. Salivary cortisol and cortisone in the clinical
- 387 setting. Current Opinion in Endocrinology, Diabetes and Obesity2017. pp 161–168.

388 (doi:10.1097/MED.0000000000328)

- 389 3. Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori
- 390 VM, & Edwards H. The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical
- 391 Practice Guideline. *The Journal of Clinical Endocrinology and Metabolism* 2008 **93**

392 1526. (doi:10.1210/JC.2008-0125)

- 393 4. Perogamvros I, Keevil BG, Ray DW, & Trainer PJ. Salivary Cortisone Is a Potential
- 394 Biomarker for Serum Free Cortisol. *The Journal of Clinical Endocrinology* &

395 *Metabolism* 2010 **95** 4951–4958. (doi:10.1210/JC.2010-1215)

- 396 5. Debono M, Harrison RF, Whitaker MJ, Eckland D, Arlt W, Keevil BG, & Ross RJ. Salivary
- 397 Cortisone Reflects Cortisol Exposure Under Physiological Conditions and After
- 398 Hydrocortisone. *The Journal of clinical endocrinology and metabolism* 2016 **101**
- 399 1469–1477. (doi:10.1210/JC.2015-3694)
- 400 6. Tryphonopoulos PD, Letourneau N, & Azar R. Approaches to Salivary Cortisol
- 401 Collection and Analysis in Infants. *Biological Research for Nursing* 2014 **16** 398–408.
- 402 (doi:10.1177/1099800413507128)
- 403 7. Adam EK & Kumari M. Assessing salivary cortisol in large-scale, epidemiological

404 research. *Psychoneuroendocrinology* 2009 **34** 1423–1436.

405 (doi:10.1016/J.PSYNEUEN.2009.06.011)

- 406 8. Dimolareva M, Gee NR, Pfeffer K, Maréchal L, Pennington K, & Meints K. Measuring
- 407 cortisol in the classroom with school-aged children—a systematic review and
- 408 recommendations. International Journal of Environmental Research and Public Health
- 409 2018 **15** . (doi:10.3390/IJERPH15051025)
- 410 9. Kidd S, Midgley P, Lone N, Michael Wallace A, Nicol M, Smith J, & McIntosh N. A re-
- 411 investigation of saliva collection procedures that highlights the risk of potential
- 412 positive interference in cortisol immunoassay. *Steroids* 2009 **74** 666–668.
- 413 (doi:10.1016/J.STEROIDS.2009.02.009)
- 414 10. Shirtcliff EA, Allison AL, Armstrong JM, Slattery MJ, Kalin NH, & Essex MJ. Longitudinal
- 415 stability and developmental properties of salivary cortisol levels and circadian
- 416 rhythms from childhood to adolescence. *Developmental Psychobiology* 2012 54 493–
- 417 502. (doi:10.1002/dev.20607)
- 418 11. Harrison D, Johnston L, Spence K, Gillies D, & Nagy S. Salivary cortisol measurements
- 419 in sick infants: A feasible and objective method of measuring stress? *Journal of*
- 420 *Neonatal Nursing* 2005 **11** 10–17. (doi:10.1016/J.JNN.2005.04.001)
- 421 12. Zwissig M, Rio L, Roth-Kleiner M, & Ramelet ASS. Measurement of stress in stable
- 422 neonates during ambulance transportation: A feasibility study. *Australian Critical Care*
- 423 2018 **32** 28–33. (doi:10.1016/j.aucc.2018.06.006)
- 424 13. Sbardella E, Isidori AM, Woods CP, Argese N, Tomlinson JW, Shine B, Jafar-
- 425 Mohammadi B, & Grossman AB. Baseline morning cortisol level as a predictor of
- 426 pituitary-adrenal reserve: a comparison across three assays. *Clinical endocrinology*
- 427 2017 **86** 177–184. (doi:10.1111/CEN.13232)
- 428 14. Toone RJ, Peacock OJ, Smith AA, Thompson D, Drawer S, Cook C, & Stokes KA.
- 429 Measurement of steroid hormones in saliva: Effects of sample storage condition.

430 *http://dx.doi.org/10.3109/00365513.2013.835862* 2013 **73** 615–621.

431 (doi:10.3109/00365513.2013.835862)

432 15. Nalla AA, Thomsen G, Knudsen GM, & Frokjaer VG. The effect of storage conditions

433 on salivary cortisol concentrations using an Enzyme Immunoassay. *Scandinavian*

434 Journal of Clinical and Laboratory Investigation 2015 **75** 92–95.

435 (doi:10.3109/00365513.2014.985252)

436 16. Ford LR, Willi SM, Hollis BW, & Wright NM. Suppression and recovery of the neonatal

437 hypothalamic-pituitary-adrenal axis after prolonged dexamethasone therapy. *The*

438 *Journal of pediatrics* 1997 **131** 722–726. (doi:10.1016/S0022-3476(97)70100-8)

439 17. Blair J, Lancaster G, Titman A, Peak M, Newlands P, Collingwood C, Chesters C,

440 Moorcroft T, Wallin N, Hawcutt D, Gardner C, Didi M, Lacy D, & Couriel J. Early

441 morning salivary cortisol and cortisone, and adrenal responses to a simplified low-

442 dose short Synacthen test in children with asthma. *Clinical endocrinology* 2014 **80**

443 376–383. (doi:10.1111/CEN.12302)

18. Broersen LHA, Pereira AM, Jørgensen JOL, & Dekkers OM. Adrenal Insufficiency in

445 Corticosteroids Use: Systematic Review and Meta-Analysis. *The Journal of Clinical*

446 *Endocrinology & Metabolism* 2015 **100** 2171–2180. (doi:10.1210/JC.2015-1218)

447 19. Tran TN, King E, Sarkar R, Nan C, Rubino A, O'Leary C, Muzwidzwa R, Belton L, & Quint

448 JK. Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and

449 the UK. *European Respiratory Journal* 2020 **55**. (doi:10.1183/13993003.02363-2019)

450 20. Ross C, Rab E, Colyer S, & Elder C. A cost-benefit analysis of the routine measurement

451 of ACTH as part of the Short Synacthen Test. *Endocrine Abstracts* 2021 **78**.

452 (doi:10.1530/ENDOABS.78.P3)

453 21. Gomar-Vercher S, Simón-Soro A, Montiel-Company JM, Almerich-Silla JM, & Mira A.

- 454 Stimulated and unstimulated saliva samples have significantly different bacterial
- 455 profiles. *PLOS ONE* 2018 **13** e0198021. (doi:10.1371/JOURNAL.PONE.0198021)
- 456 22. Fernandes A, Skinner ML, Woelfel T, Carpenter T, & Haggerty KP. Implementing Self-
- 457 collection of Biological Specimens With a Diverse Sample. *Field methods* 2013 **25** 58–
- 458 73. (doi:10.1177/1525822X12453526)
- 459 23. Bäumler D, Kirschbaum C, Kliegel M, Alexander N, & Stalder T. The cortisol awakening
- 460 response in toddlers and young children. *Psychoneuroendocrinology* 2013 **38** 2485–
- 461 2492. (doi:10.1016/j.psyneuen.2013.05.008)
- 462 24. Novak D. A Novel Saliva Collection Method among Children and Infants: A
- 463 Comparison Study between Oral Swab and Pacifier-based Saliva Collection. *Journal of*
- 464 *Contemporary Dental Practice* 2021 **22** 9–12. (doi:10.5005/jp-journals-10024-3028)
- 465 25. Chen B, Lyu H, Xu X, & Wang C. Simultaneous Quantification of Cortisol and Cortisone
- 466 in Serums and Saliva from Depressive Patients by Supported Liquid Extraction
- 467 Coupled to HPLC-MS/MS. *Acta Chromatographica* 2020 **32** 269–275.
- 468 (doi:10.1556/1326.2020.00733)
- 469 26. Jones RL, Owen LJ, Adaway JE, & Keevil BG. Simultaneous analysis of cortisol and
- 470 cortisone in saliva using XLC–MS/MS for fully automated online solid phase
- 471 extraction. *Journal of Chromatography B* 2012 **881–882** 42–48.
- 472 (doi:10.1016/J.JCHROMB.2011.11.036)
- 473 27. Tonge JJ, Keevil BG, Craig JN, Whitaker MJ, Ross RJ, & Elder CJ. Supplementary data
- 474 for: Salivary steroid collection in children under conditions replicating home sampling.
- 475 *Zenedo, dataset.* 2022. (doi:10.5281/ZENODO.6800272)
- 476 28. Clements AD & Richard Parker C. The relationship between salivary cortisol
- 477 concentrations in frozen versus mailed samples. *Psychoneuroendocrinology* 1998 23

- 478 613–616. (doi:10.1016/S0306-4530(98)00031-6)
- 479 29. Garde AH & Hansen ÅM. Long-term stability of salivary cortisol. *Scandinavian Journal*480 of *Clinical and Laboratory Investigation* 2005 **65** 433–436.
- 481 (doi:10.1080/00365510510025773)
- 482 30. Donzella B, Talge NM, Smith TL, & Gunnar MR. To spear or not to spear: Comparison
- 483 of saliva collection methods. *Developmental Psychobiology* 2008 **50** 714–717.
- 484 (doi:10.1002/dev.20340)
- 485 31. Soliman H, Elsharkawy A, & Abdel-Hady H. Does topical lidocaine reduce the pain
- 486 associated with the insertion of nasal continuous positive airway pressure prongs in
- 487 preterm infants?: A randomized, controlled pilot trial. *Clinical Journal of Pain* 2016 **32**

488 948–954. (doi:10.1097/AJP.00000000000341)

- 489 32. Mohanan A, Varma B, Kumar S, Kumaran P, & Xavier A. Assessment of Salivary Flow
- 490 Rate and Antioxidant Levels in Ectodermal Dysplasia Patients: An In vivo Study.
- 491 *Contemporary Clinical Dentistry* 2019 **10** 74. (doi:10.4103/CCD.CCD_358_18)
- 492 33. Riedy CA, Milgrom P, Ly KA, Rothen M, Mueller G, Hagstrom MK, Tolentino E, Zhou L,
- 493 & Roberts MC. A surrogate method for comparison analysis of salivary concentrations
- 494 of Xylitol-containing products. *BMC Oral Health* 2008 **8** 1–8. (doi:10.1186/1472-6831-
- 495 8-5/TABLES/2)
- 496 34. Ng SM & Drury JA. Correlation of Plasma and Salivary Cortisol in Extremely Premature
- 497 Infants Telomerase and telomere biology in normal endometrial function and in
- 498 pathological conditions View project Donatella Pintus View project Ng et al. Article in
- 499 *Journal of Neonatal Biology* 2017 **6** 3. (doi:10.4172/2167-0897.1000260)
- 500 35. Sørensen SO, Pedersen J, Rasmussen MG, Kristensen PL, & Grøntved A. Feasibility of
- 501 home-based sampling of salivary cortisol and cortisone in healthy adults. BMC

502 research notes 2021 **14**. (doi:10.1186/S13104-021-05820-4)

- 503 36. Valentine-Graves M, Hall E, Guest JL, Adam E, Valencia R, Shinn K, Hardee I, Sanchez
- 504 T, Siegler AJ, & Sullivan PS. At-home self-collection of saliva, oropharyngeal swabs and
- 505 dried blood spots for SARS-CoV-2 diagnosis and serology: Post-collection acceptability
- 506 of specimen collection process and patient confidence in specimens. *PLOS ONE* 2020
- 507 **15** e0236775. (doi:10.1371/JOURNAL.PONE.0236775)
- 508 37. Emami A, Hallinder H, Theorell T, Kim H, & Engström G. The Feasibility and
- 509 Acceptability of In-Home Saliva Collection for Stress in Persons With Dementia and
- 510 Their Family Caregivers. *Biological research for nursing* 2022 **24**.
- 511 (doi:10.1177/10998004221076554)
- 512 38. Roth R, Baxter J, Vehik K, Hopkins D, Killian M, Gesualdo P, Melin J, Simell B, Strauss E,
- 513 Lernmark Å, & Johnson SB. The Feasibility of Salivary Sample Collection in an
- 514 International Pediatric Cohort: the TEDDY Study. *Developmental psychobiology* 2017
- 515 **59** 658. (doi:10.1002/DEV.21523)
- 516 39. Mandrell BN, Avent Y, Walker B, Loew M, Tynes BL, & Crabtree VML. In-home salivary
- 517 melatonin collection: Methodology for children and adolescents. *Developmental*
- 518 *Psychobiology* 2018 **60** 118–122. (doi:10.1002/DEV.21584)
- 519 40. Qureshi AC, Bahri A, Breen LA, Barnes SC, Powrie JK, Thomas SM, & Carroll P V. The
- 520 influence of the route of oestrogen administration on serum levels of cortisol-binding
- 521 globulin and total cortisol. *Clinical endocrinology* 2007 **66** 632–635.
- 522 (doi:10.1111/J.1365-2265.2007.02784.X)
- 523 41. Manetti L, Rossi G, Grasso L, Raffaelli V, Scattina I, Sarto S Del, Cosottini M, Iannelli A,
- 524 Gasperi M, Bogazzi F, & Martino E. Usefulness of salivary cortisol in the diagnosis of
- 525 hypercortisolism: comparison with serum and urinary cortisol. *European Journal of*

- *Endocrinology* 2013 **168** 315–321. (doi:10.1530/EJE-12-0685)
- 527 42. Wilson M & Thayer Z. Maternal salivary cortisone to cortisol ratio in late pregnancy:
- 528 An improved method for predicting offspring birth weight. *Psychoneuroendocrinology*
- 529 2017 **78** 10–13. (doi:10.1016/J.PSYNEUEN.2016.12.018)

| 535 | Figure | Legen | ds: |
|-----|--------|-------|-----|
|-----|--------|-------|-----|

| 537 | Figure 1. Salivary collection techniques: 1a. Salivette® Cortisol (Sarstedt, Germany), 1b. |
|-----|---|
| 538 | Passive drool (Salicap, IBL International, Germany) and 1c. SalivaBio swab (Salimetrics, USA). |
| 539 | |
| 540 | Figure 2. SaliPac [™] salivary collection device: (a) SalivaBio swab (<i>Salimetrics, California,</i> |
| 541 | USA); (b) indicator line and (c) plastic back cover. Indicator line drawn to allow |
| 542 | approximately 1mL of salivary collection. |
| 543 | |
| | |
| 544 | Figure 3. Median % change in salivary cortisol (a) and salivary cortisone (b) concentration |
| 545 | when stored refrigerated, frozen and at room temperature over the one-week study |
| 546 | period. Glucocorticoid concentration measured in nmol/L. Changes in concentration are |
| 547 | compared to the mean values from the reference samples frozen immediately after |
| 548 | collection (salivary cortisol 3.675 nmol/L and salivary cortisone 21.7 nmol/L). The dashed |
| 549 | lines at 10% degradation indicate the cut off set as acceptable stability. |
| 550 | |
| 551 | Figure 4. Median % change in salivary cortisol (a) and salivary cortisone (b) concentration |
| 552 | following four freeze-thaw cycles. Glucocorticoid concentration measured in nmol/L. |
| 553 | Changes in concentration are compared to the mean values from the reference samples |
| 554 | frozen immediately after collection (salivary cortisol 3.675 nmol/L and salivary cortisone |
| 555 | 21.7 nmol/L). The dashed lines at 10% degradation indicate the cut off set as acceptable |
| 556 | stability. |
| | |

Tables:

- Table 1. Comparison of salivary glucocorticoid levels following collection using three
 salivary collection techniques: Salivette® Cortisol (Sarstedt, Germany), passive drool
 (Salicap, IBL International, Germany) and SalivaBio (Salimetrics, USA). N=270 salivary
 samples, 90 collected using each collection technique, taken from six healthy adult
 volunteers.

| Salivary Glucocorticoid (nmol/L) | Saliva collection techniques compared | Mean Difference | Standard Deviation | 95% Confidence Interval |
|--|--|--------------------|-----------------------|-------------------------------|
| | SalivaBio vs Salivette | -0.226 | 0.915 | -0.957 to 0.410 |
| Cortisol | SalivaBio vs Passive Drool | -0.751 | 2.834 | -2.928 to 1.425 |
| | Salivette vs Passive Drool | 0.214 | 1.301 | -1.087 to 1.729 |
| | | | | |
| | SalivaBio vs Salivette | -1.516 | 3.548 | -4.242 to 1.210 |
| Cortisone | SalivaBio vs Passive Drool | 0.871 | 5.140 | -3.001 to 4.745 |
| | Salivette vs Passive Drool | 1.029 | 3.309 | -2.280 to 4.338 |
| | | | | |

| 566 | | | |
|-----|--|--|--|
| 567 | | | |
| 568 | | | |
| 569 | | | |
| 570 | | | |
| 571 | | | |
| 572 | | | |
| 573 | | | |
| 574 | | | |

Table 2. Salivary cortisol concentrations following storage under different time and
temperature conditions. Salivary cortisol stored on a SalivaBio swab (Salimetrics, USA).
N=96 salivary samples taken from six healthy adult volunteers. Baseline denotes the mean
salivary cortisol value from the reference samples, 3.675 nmol/L. *indicates a statistically
significant difference.

| | | S | itorage temperature | |
|-----------------------------------|----------------------------------|---------------|---------------------|---------------|
| Time at storage temperature | Salivary cortisol (nmol/L) | 4°C | Room temperature | 50°C |
| | Mean ± SD | 3.523 ± 1.866 | 3.662 ± 2.099 | 3.545 ± 1.855 |
| 24 hours | % Difference from baseline | -2.90% | -3.51% | -5.77% |
| | p-value | 0.086 | 0.928 | 0.318 |
| | Mean ± SD | 3.465 ± 2.005 | 3.430 ± 1.890 | 3.435 ± 1.999 |
| 48 hours | % Difference from baseline | -6.33% | -6.94% | -5.58% |
| | p-value | 0.083 | 0.060 | 0.055 |
| | Mean ± SD | 3.577 ± 1.902 | 3.470 ± 1.877 | 3.362 ± 1.847 |
| 72 hours | % Difference from baseline | -3.71% | -5.66% | -6.54% |
| | p-value | 0.352 | 0.066 | 0.090 |
| | Mean ± SD | 3.357 ± 2.009 | 3.597 ± 1.932 | 2.962 ± 1.469 |
| 1 week | % Difference from baseline | -8.82% | -2.02% | -20.09% |
| | p-value | 0.041* | 0.458 | 0.044* |

Table 3. Salivary cortisone concentrations following storage under different time and
 temperature conditions. Salivary cortisone stored on a SalivaBio swab (Salimetrics, USA).
 N=96 salivary samples taken from six healthy adult volunteers. Baseline denotes the mean
 salivary cortisone value from the reference samples, 21.70 nmol/L. *indicates a statistically
 significant difference.

| | | Storage temperature | | |
|-----------------------------------|-----------------------------------|---------------------|---------------------|----------------|
| Time in storage temperature | Salivary cortisone (nmol/L) | 4°C | Room temperature | 50°C |
| | Mean ± SD | 21.040 ± 8.030 | 21.943 ± 9.436 | 20.430 ± 7.910 |
| 24 hours | % Difference from baseline | -2.03% | +1.27% | -7.43% |
| | p-value | 0.232 | 0.737 | 0.048* |
| | Mean ± SD | 21.208 ± 8.551 | 20.528 ± 8.377 | 19.227 ± 7.749 |
| 48 hours | % Difference from baseline | -4.24% | -7.37% | -11.74% |
| | p-value | 0.399 | 0.770 | 0.002* |
| | Mean ± SD | 20.903 ± 8.149 | 20.202 ± 7.762 | 18.963 ± 7.601 |
| 72 hours | % Difference from | -5.10% | -5.27% | -14.12% |
| | p-value | 0.236 | 0.080 | 0.009* |
| | Mean ± SD | 21.418 ± 8.609 | 19.575 ± 7.155 | 15.490 ± 5.950 |
| 1 week | % Difference from baseline | -3.40% | -10.83% | -25.62% |
| | p-value | 0.415 | 0.012* | 0.012* |

Table 4. Comparison of the time taken to collect sufficient saliva for glucocorticoid analysis from infants and young children using the SalivaBio (Salimetrics, USA) alone and within the SaliPac, under hospital and simulated home conditions. "Real world time" describes the total time taken in seconds from the swab entering the child's mouth to the caregiver completing the sampling and "actual collection time" the time taken to collect 1mL of saliva, with the timer stopped if the SaliPac or SalivaBio is expelled from the mouth. *Denotes a statistically significant difference.

| | - | SalivaBio N=30 | SaliPac N=26 | p-value |
|----------------|---|------------------------------|------------------------------|---------|
| Overall | Mean Real world collection time (seconds) | 122.30 ± 37.33 (42 – 210) | 131.58 ± 30.70 (73 – 229) | 0.319 |
| | Mean Actual collection time (seconds) | 118.87 ± 32.42 (42 – 210) | 131.38 ± 30.72 (73 – 229) | 0.146 |
| Hospital | Mean Real world collection time (seconds) | 120.50 ± 33.04 (42 - 189) | 135.19 ± 32.01 (84 - 210) | 0.321 |
| Condition | Mean Actual collection time (seconds) | 118.25 ± 29.32 (42 - 189) | 133.87 ± 30.08 (84 - 210) | 0.716 |
| Simulated | Mean Real world collection time (seconds) | 125.90 ± 46.52 (89 - 188) | 125.80 ± 29.15 (81 - 172) | 0.459 |
| home Condition | Mean Actual collection time (seconds) | 124.88 ± 45.58 (89 - 188) | 122.78 ± 28.06 (81 - 172) | 0.952 |

599 600

598

601

- 603 Table 5. Acceptability of salivary collection from infants and young children using the
- 604 SalivaBio (*Salimetrics, USA*) alone and within the SaliPac[™], under hospital and stimulated
- 605 home conditions assessed by caregiver questionnaire. Ease of use assessed caregivers'
- ability to complete salivary collection independently using a patient information leaflet.
 - SaliPac SalivaBio p-value N=30 N=26 Ease of use score α 8.2 9.8 0.012* Acceptability score ^α 8.2 9.8 0.012* Caregiver Questionnaire Parent/carer 22 3 preference 0.001* (15%) (85%) **Child preference** 1 25 0.001* (4%) (96%)
- 607 *denotes a statistically significant difference.

608 α = Mean score out of 10.